Discovery and characterization of a high-affinity and high-specificity peptide ligand LXY30 for in vivo targeting of α3 integrin-expressing human tumors

EJNMMI Research

Volumn 6, Issue 1, 2016, Pages 1-12

  Xiao, Wenwu ^a   Li, Tianhong ^a,b,c   Bononi, Fernanda C ^a   Lac, Diana ^a   Kekessie, Ivy A ^a   Liu, Yanlei ^a   Sanchez, Eduardo ^a   Mazloom, Anisha ^a   Ma, Ai hong ^a   Lin, Jia ^a   Tran, Jimmy ^a   Yang, Kevin ^a,d   Lam, Kit S ^a,b   Liu, Ruiwu ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer targeting peptide; Glioblastoma; One bead one compound combinatorial peptide library; Optical imaging; 3 1 integrin

Indexed keywords

ALPHA3 INTEGRIN; CYCLOPEPTIDE; LIGAND; PEPTIDE LIGAND LXY30; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOLUMINESCENCE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ELECTROSPRAY; ENZYME SPECIFICITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA CELL LINE; IC50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 84959330716     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-016-0165-z     Document Type: Article

References (33)

1. Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium. 2006;13:113–35. doi:10.1080/10623320600698037.
2. Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics. 2011;1:154–88.
3. Marelli UK, Rechenmacher F, Sobahi TR, Mas-Moruno C, Kessler H. Tumor targeting via integrin ligands. Front Oncol. 2013;3:222. doi:10.3389/fonc.2013.00222.
4. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med. 1999;222:124–38.
5. Paulus W, Baur I, Schuppan D, Roggendorf W. Characterization of integrin receptors in normal and neoplastic human brain. Am J Pathol. 1993;143:154–63.
6. Xiao K, Li Y, Lee JS, Gonik AM, Dong T, Fung G, et al. “OA02” peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res. 2012;72:2100–10. doi:10.1158/0008-5472.CAN-11-3883.
7. Coopman PJ, Thomas DM, Gehlsen KR, Mueller SC. Integrin alpha 3 beta 1 participates in the phagocytosis of extracellular matrix molecules by human breast cancer cells. Mol Biol Cell. 1996;7:1789–804.
8. Patriarca C, Ivanyi D, Fles D, de Melker A, van Doornewaard G, Oomen L, et al. Distribution of extracellular and cytoplasmic domains of the alpha 3 and alpha 6 integrin subunits in solid tumors. Int J Cancer. 1995;63:182–9.
9. Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R, et al. The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer. 2000;87:336–42.
10. Gogali A, Charalabopoulos K, Constantopoulos S. Integrin receptors in primary lung cancer. Exp Oncol. 2004;26:106–10.
11. Takenaka K, Shibuya M, Takeda Y, Hibino S, Gemma A, Ono Y, et al. Altered expression and function of beta1 integrins in a highly metastatic human lung adenocarcinoma cell line. Int J Oncol. 2000;17:1187–94.
12. Varzavand A, Drake JM, Svensson RU, Herndon ME, Zhou B, Henry MD, et al. Integrin alpha3beta1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization. Clin Exp Metastasis. 2013;30:541–52. doi:10.1007/s10585-012-9558-1.
13. Yoshimasu T, Sakurai T, Oura S, Hirai I, Tanino H, Kokawa Y, et al. Increased expression of integrin alpha3beta1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line. Cancer Sci. 2004;95:142–8.
14. Zhou B, Gibson-Corley KN, Herndon ME, Sun Y, Gustafson-Wagner E, Teoh-Fitzgerald M, et al. Integrin alpha3beta1 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma. Mol Cancer Res. 2014;12:143–54. doi:10.1158/1541-7786.mcr-13-0184.
15. Aina OH, Marik J, Liu R, Lau DH, Lam KS. Identification of novel targeting peptides for human ovarian cancer cells using “one-bead one-compound” combinatorial libraries. Mol Cancer Ther. 2005;4:806–13. doi:10.1158/1535-7163.MCT-05-0029.
16. Xiao W, Yao N, Peng L, Liu R, Lam KS. Near-infrared optical imaging in glioblastoma xenograft with ligand-targeting alpha 3 integrin. Eur J Nucl Med Mol Imaging. 2009;36:94–103. doi:10.1007/s00259-008-0920-0.
17. Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol. 2006;2:381–9. doi:10.1038/nchembio798.
18. Xiao W, Wang Y, Lau EY, Luo J, Yao N, Shi C, et al. The use of one-bead one-compound combinatorial library technology to discover high-affinity alphavbeta3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle. Mol Cancer Ther. 2010;9:2714–23. doi:10.1158/1535-7163.MCT-10-0308.
19. Lam KS, Salmon SE, Hersh EM, Hruby VJ, Kazmierski WM, Knapp RJ. A new type of synthetic peptide library for identifying ligand-binding activity. Nature. 1991;354:82–4. doi:10.1038/354082a0.
20. Lam KS, Lebl M, Krchnak V. The “one-bead-one-compound” combinatorial library method. Chem Rev. 1997;97:411–48.
21. Lau D, Guo L, Liu R, Marik J, Lam K. Peptide ligands targeting integrin alpha3beta1 in non-small cell lung cancer. Lung Cancer. 2006;52:291–7. doi:10.1016/j.lungcan.2006.03.003.
22. Yao N, Xiao W, Wang X, Marik J, Park SH, Takada Y, et al. Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method. J Med Chem. 2009;52:126–33. doi:10.1021/jm801062d.
23. Yao N, Xiao W, Meza L, Tseng H, Chuck M, Lam KS. Structure-activity relationship studies of targeting ligands against breast cancer cells. J Med Chem. 2009;52:6744–51. doi:10.1021/jm9012032.
24. Darlak K, Wiegandt Long D, Czerwinski A, Darlak M, Valenzuela F, Spatola AF, et al. Facile preparation of disulfide-bridged peptides using the polymer-supported oxidant CLEAR-OX. J Pept Res. 2004;63:303–12. doi:10.1111/j.1399-3011.2004.00153.x.
25. Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol. 2015;33:306–12. doi:10.1038/nbt.3080.
26. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm. 2007;4:631–51. doi:10.1021/mp700073y.
27. Guo L, Zhang F, Cai Y, Liu T. Expression profiling of integrins in lung cancer cells. Pathol Res Pract. 2009;205:847–53. doi:10.1016/j.prp.2009.07.005.
28. Cagnet S, Faraldo MM, Kreft M, Sonnenberg A, Raymond K, Glukhova MA. Signaling events mediated by alpha3beta1 integrin are essential for mammary tumorigenesis. Oncogene. 2014;33:4286–95. doi:10.1038/onc.2013.391.
29. Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract. 2012;2012:283181. doi:10.1155/2012/283181.
30. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. doi:10.3322/caac.21166.
31. Soffietti R, Trevisan E, Ruda R. Targeted therapy in brain metastasis. Curr Opin Oncol. 2012;24:679–86. doi:10.1097/CCO.0b013e3283571a1c.
32. Fokas E, Steinbach JP, Rodel C. Biology of brain metastases and novel targeted therapies: time to translate the research. Biochim Biophys Acta. 1835;2013:61–75. doi:10.1016/j.bbcan.2012.10.005.
33. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005;75:5–14. doi:10.1007/s11060-004-8093-6.